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Abstract
Context—Early detection and prospective evaluation of clinical high-risk (CHR) individuals who
may develop schizophrenia or other psychotic disorders is critical for predicting psychosis onset
and for testing preventive interventions.
Objective—To elucidate the neuropsychology of the CHR syndrome, to determine the
association of neuropsychological function with conversion to psychosis and family history (FH)
of psychosis, and to examine whether baseline neuropsychological functioning predicts
subsequent psychosis.
Design, Setting, and Participants—Longitudinal study with 2 1/2 years follow-up of 304
prospectively identified CHR individuals meeting Structured Interview for Prodromal Syndromes
(SIPS) criteria, 52 non-CHR persons with a FH of psychosis in first- or second-degree relatives
(“family HR”/FHR), and 193 normal controls with neither a FH of psychosis nor a CHR
syndrome, all of whom had baseline neuropsychological evaluations, recruited across eight centers
as part of the North American Prodrome Longitudinal Study (NAPLS).
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Main Measures—A neurocognitive composite score, eight individual neuropsychological
measures, an IQ estimate, and HR status.
Results—Global (“composite”) neuropsychological functioning was comparably impaired in
CHR and FHR groups compared to controls, but profiles differed significantly between groups.
Neuropsychological functioning in the CHR group was significantly lower in persons who
progressed to psychosis than in those who did not, and worst in the subgroup with a FH of
psychosis. Tests of processing speed and verbal learning and memory were most sensitive in
discriminating CHR from controls, although reductions were less severe than in established
schizophrenia. Neuropsychological functioning did not contribute uniquely to the prediction of
psychosis beyond clinical criteria, but worse verbal memory predicted more rapid conversion.
Conclusion—These findings document that CHR individuals have significant
neuropsychological difficulties, particularly those who later develop psychosis. This dysfunction
is generally of moderate severity but less than in first episode schizophrenia, suggesting that a
further decline may occur after baseline CHR assessment.
Substantial neuropsychological deficits, first described by Kraepelin1 and Bleuler2, have
subsequently been observed in all phases of schizophrenia, beginning in the premorbid
period and continuing throughout life. Patients in the first psychotic episode and during
chronic periods manifest large neuropsychological impairments with effect sizes (ES)
averaging approximately 1.03,4. The degree of impairment depends on the domain
measured, with verbal memory and processing speed typically eliciting the largest deficits
(ES = 1.3–1.6 using Cohen’s d)3,4. Moreover, because neuropsychological functions are
important as windows into pathophysiology5 and because they are strongly associated with
functional outcomes in schizophrenia6, they may be important in risk prediction of
psychosis.
The robust finding of premorbid neuropsychological impairment indicates that these
measures may have utility as predictors of schizophrenia, an idea frequently evaluated in
persons at genetic (familial) high risk ([F]HR)7–9, and recently in clinical high risk (CHR)
or putatively “prodromal” samples10. CHR requires the presence of specific subsyndromal
psychotic symptoms, while FHR is defined solely by the presence of a family history (FH)
of psychosis.
Compared to healthy control subjects, ESs of neuropsychological deficits in offspring8,9 and
adult, non-psychotic relatives of persons with schizophrenia range between 0.3–0.6,
reflecting moderate deficits in the absence of psychosis11–15. These findings suggest that
cognitive deficits are associated with the neural substrates of the illness16–17 and that they
may be attributable largely to inherited variations16,18. These impairments have considerable
validity because they are not confounded by psychosis or medications. Commonly identified
deficits in FHR samples include lower verbal ability, general intelligence (“IQ”), declarative
and working memory, sustained attention, processing speed, executive and motor
functions7,8,11–15,17,19,20.
While identification of neuropsychological impairments in FHR studies supports a
neurodevelopmental model of vulnerability to schizophrenia20–22, their utility for prediction
of psychosis is limited by modest lifetime conversion rates of approximately 10%. The
problem of relatively low conversion rates in FHR samples and the notion that early
detection and intervention may prevent clinical expression of psychosis or functional
deterioration have stimulated a new direction in psychiatry research aimed at reducing
morbidity and mortality23, similar to prevention efforts in other branches of medicine24,25.
This approach has focused on developing and validating criteria for ascertaining individuals
at risk for imminent onset of psychosis and following them over time26–28. Advantages of
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this approach over FHR methods include more efficient timing of assessments proximate to
illness onset and reduction of false positive rates29,30. Because the modal period of onset in
schizophrenia is between ages 18–30, “case identification” during adolescence and young
adulthood is essential.
Over the past five years, at least 10 research groups have published studies of
neuropsychological functioning in CHR samples10. Findings from cross-sectional CHR
studies have consistently documented that neuropsychological deficits are intermediate
between control and first episode psychosis samples10,31–54, and one has shown that
neuropsychological functioning is related to illness course50. Several specific deficits have
been observed, most reliably in spatial35–38 and verbal46 working memory, verbal
declarative memory39,40,43,52, and attention31,32,40–44,48. Deficits in olfaction47 and
executive functions, as measured by verbal fluency, matrices, and set-shifting, and visual
form perception, have been less consistently tested or identified31,32,35,36,40,43,46–48,52,54.
Some deficits (e.g., in sustained attention) may represent stable vulnerability markers40,41,
while others (such as in verbal memory, working memory, processing speed and verbal
IQ53) may be predictive of conversion to psychosis39,40,48,49,53.
Despite substantial progress, variability in test batteries and small samples complicate
interpretation. Moreover, only two studies36,51 have integrated FHR and CHR methods, and
the few studies that compared individuals who do and do not convert to illness are limited
by small samples and brief follow-ups. Because many patients with neuropsychiatric
disorders manifest neuropsychological deficits, it is important to compare those CHR
individuals who develop psychosis with those who do not. Longitudinal designs including
follow-up into conversion may identify neuropsychological deficits that predict psychosis.
The North American Prodrome Longitudinal Study (NAPLS) is a consortium of eight
research centers, ascertaining CHR individuals and following them for a period of up to
2-1/2 years30,55,56. Although originally developed as independent studies, the sites
employed similar ascertainment and diagnostic methods, making it possible to form a
standardized protocol for mapping data into a new scheme representing the common
components across sites30,55, yielding the largest database of longitudinally followed CHR
cases worldwide.
The primary aims of this study are to characterize the neuropsychology of the psychosis
prodrome by comparing CHR performance to normal controls and FHR, and to examine the
value of neuropsychological function for predicting conversion to psychosis. Our hypotheses
were that persons who subsequently convert to psychosis are more impaired at baseline than
non-converters, that this effect would be amplified in persons with a FH of psychosis, and




Study protocols and informed consent documents, including procedures for data pooling and
secondary data analysis, were approved by the Institutional Review Boards of the
participating sites (Emory University, Harvard University, University of California Los
Angeles [UCLA], University of California San Diego [UCSD], University of North Carolina
(UNC), University of Toronto (UT), Yale University, and Zucker Hillside Hospital in New
York). NAPLS methods and details of the federated database not specific to the present
study are described elsewhere30,55,56. Nine reports of neuropsychological function have
been published on four smaller CHR samples by NAPLS centers: three from the PRIME
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multi-site study (including Yale, UNC and UT sites) 31,32,33, two from Zucker-Hillside37,40,
two from UCLA44,49 and two from UCSD48,49. However, these neuropsychological data
were not previously combined, did not include a 2.5 year follow-up (a smaller PRIME study
included 2-year follow-up33), and did not evaluate the impact of neuropsychological
functioning on conversion to psychosis, in relation to FH and other possible predictors.
Participants from the NAPLS database who completed any baseline neuropsychological
testing were included, yielding 304 CHR individuals, 52 persons with a FH of psychosis
without prodromal symptoms, and 193 normal controls without a FH of psychosis or
prodromal symptoms. Of the 304 CHR subjects, 269 (89%) were followed for up to 2-1/2
years to assess for conversion to psychosis. The 35 CHR participants without any follow-up
were excluded from analyses that take conversion status into account. Of the 304 CHR
subjects, 89 (29%) converted to psychosis, of whom 73 (82%) had baseline neurocognitive
data.
Assessment Procedures
The Structured Interview for Prodromal Syndromes (SIPS)57–58 criteria was used for study
entry, and the Structured Clinical Interview for DSM-IV59 (SCID)60 was most commonly
used to assess general psychopathology. SIPS criteria57 for a CHR syndrome emphasize
onset or worsening of attenuated positive symptoms in the past 12 months in at least one of
five symptom domains: unusual thought content, suspicion/paranoia, grandiosity, perceptual
anomalies, and disorganized communication. Subjects also qualified for a CHR syndrome if
they showed onset of brief intermittent positive psychotic symptoms in the past 3 months
but below the threshold required for a DSM-IV Axis I psychotic disorder diagnosis, or if
they had a genetic risk for psychosis and deterioration of 30% or more on the Global
Assessment of Functioning scale in the past 12 months, where genetic risk is defined by
having a FH of psychosis or a diagnosis of schizotypal personality disorder.61,62 All NAPLS
sites demonstrated good reliability employing the SIPS criteria (κ’s ranged from .80 to 1.00
across sites).57 At each site, raters were MA, PhD, or MD specialists in mental health.
Follow-Up Assessments
The SIPS was re-administered at 6-month intervals up to 30 months. If clinical deterioration
was observed during interim periods, a re-assessment was conducted before regularly
scheduled assessments. Because treatment was not standardized, information on dosing and
duration of antipsychotic treatments was unavailable for the majority of cases.
Baseline NAPLS Neuropsychological Assessment Protocol
Cognitive performance variables presented unique challenges in the development of an
omnibus protocol.57 Sixty-eight different neurocognitive measures derived from 40 separate
tests were used across sites. Criteria for test inclusion in the federated database included: (1)
representation across at least four sites, (2) comparability of test versions, administration
procedures, and scoring, and (3) coverage of presumed areas of separable cognitive
impairment in schizophrenia63. Thirteen cognitive variables, derived from 8 tests, were
initially selected for the omnibus battery. However, to enhance commonality, to carry out
multivariate statistical analyses and to create a composite score for use in prediction
analyses, the number of variables examined in these analyses was reduced to eight: verbal
comprehension (Vocabulary64–67), visual-perceptual-organization (Block Design64–66),
vigilance (Continuous Performance Test – Identical Pairs [CPT-IP] digits68), speed of
processing (Digit Symbol[“Coding”]64–66 and Trail Making69 B), executive functioning
including verbal fluency (Controlled Oral Word Association [COWA] test70) and problem
solving (Wisconsin Card Sorting Test [WCST] 71–72), and verbal learning and memory
(Story Recall tests from the Wechsler Memory Scales [WMS]73,74 for participants age 17
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and older and Children’s Memory Scales [CMS] 75 for those under age 17) and list learning
on the Hopkins Verbal Learning Test (HVLT) 76, Rey Auditory Verbal Learning Test
(RAVLT)77, and California Verbal Learning Test (CVLT) adult and child versions 78,79.
Additional information regarding variable construction is available in an online supplement.
Data Analytic Plan
Data analyses consisted of two approaches: a univariate approach including all subjects for
whom data was available in an individual cognitive domain, and a multivariate approach
that included all cognitive domains and construction of a composite score. To support the
multivariate approach, a series of decision rules for acceptable subject inclusion were
created and imputation steps were implemented. This resulted in a multivariate sample
(n=325) that is a subset (60%) of the univariate sample (n=549), including reduced samples
of CHR subjects (n=167, 55% of the univariate sample), FHR (n=49, 94%), and controls
(n=109, 56%). Because of substantial subject loss in the multivariate sample, both samples
were analyzed and compared. The univariate analyses are presented in an online
supplement, and significant findings are integrated within the Results.
Formation of the Multivariate Sample—Inclusion in the multivariate sample required
subjects to have a minimum of 75% complete data (i.e., completed at least 6 of 8 tests), thus
reducing the total missing data to <10%, which was our maximum threshold for data loss
prior to imputation. Multiple imputation (MI) methods were used to address missing data. In
contrast to listwise deletion, which has the disadvantages of loss of observations and
reduced statistical power, MI permits analysis of complete data by calculating estimates of
missing values using other variables in the model as predictors80–82. Details of data
imputation methods are in the online supplement.
Group Contrasts—The groups compared were CHR, FHR and normal controls (NC).
The CHR group was further subdivided into converters to psychosis (CHR+) and non-
converters (CHR−). Six comparisons were made within both the multivariate and univariate
samples: 1). CHR vs. NC; 2). FHR vs. NC; 3). CHR vs. FHR; 4). CHR+ vs. NC; 5). CHR−
vs. NC; 6). CHR+ vs. CHR−. A small subgroup of CHR+ with a positive FH (CHR+FH+)
were analyzed within the univariate sample, due to its larger CHR+FH+ sub-sample.
Statistical Analyses—Statistical analyses were performed using SPSS version 17 or SAS
version 9.1. One-way analysis of variance (ANOVA) and chi-square tests were conducted to
compare groups on demographics. For the multivariate sample, comparison of
neuropsychological measures was conducted using multivariate ANOVA (MANOVA),
multivariate analysis of covariance (MANCOVA), univariate ANCOVA, and Profile
Analysis.
In some contrasts, groups were significantly different on education, parental education,
gender and ethnicity. Because ethnicity and parental education were correlated, and because
parental education is strongly associated with neurocognition, parental education was
controlled. In contrast, subjects’ own education is likely to be affected by illness and was not
controlled. Because small differences in age can influence neuropsychological functioning
in adolescence, analyses controlled for age, parental education and gender. We also tested
for the effects of “site”. To examine whether neuropsychological impairments were
significant beyond general intellectual impairment, we used MANCOVA controlling for
age, gender and FSIQ estimate83 (after removing Vocabulary and Block Design tests that
comprise estimated FSIQ from the profiles). To test whether the shape of
neuropsychological profiles differed for selected contrasts, unadjusted scores were analyzed
using the General Linear Model repeated measures function. For profile analyses, the 8
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measures were standardized against the normal controls within each of the 5 imputed
datasets and then pooled across imputed datasets. In addition, a composite score was
constructed as the mean of the 8 standardized scores within each imputed dataset and then
pooled.
Statistical significance was set at p < .05 using 2-tailed tests for multivariate analyses
(MANOVA, MANCOVA, profile analyses, Composite score). Bonferroni correction was
used to control the Type I error rate for univariate analyses (.05/8 or <= .00625).
Comparisons that remained significant at the Bonferroni-corrected level are bolded in the
tables and presented in Results. ESs (unadjusted) were calculated with Cohen’s d84.
Primary analyses were followed by tests of association between neurocognitive functioning
and psychosis progression for the multivariate sample. To identify the cognitive variables
most predictive of psychosis progression, we first examined the predictive value of the
baseline composite score, FSIQ, Coding and Verbal Memory in separate Cox regression
models. The latter three were chosen because they are most sensitive in FHR and
schizophrenia patients respectively3,4,8. A multivariate Cox regression using backward
selection was conducted to identify which of the 8 cognitive test scores have unique
predictive associations with conversion. A second set of multivariate Cox regressions were
used to determine whether any of the 10 cognitive variables added unique prediction beyond
the multivariate NAPLS clinical algorithm previously reported.30
RESULTS
Demographic Characteristics
Multivariate Sample—Comparing CHR and FHR participants with controls revealed no
significant group differences in age (Table 1 and Table S1). CHR subjects attained
significantly less education than controls. The FHR group showed significantly less parental
education than controls. The CHR group had significantly fewer females than the FHR and
control groups. The groups differed on race, with significantly more Caucasians in CHR
than other groups. Parental education was significantly lower in CHR+ than in CHR−.
Univariate Sample—Demographic comparisons were the same in the univariate and
multivariate sample comparisons with the following additions: 1. Parental education was
significantly lower in the CHR group than in controls; 2. There were significantly fewer
African Americans in CHR than other groups; 3. The FHR group had significantly fewer
Asian Americans than other groups; 4. CHR+ and CHR− did not differ significantly on any
variable.
The 167 CHR multivariate subjects did not differ significantly on any demographic variable
compared to the additional 137 CHR subjects who together formed the univariate sample.*
Neuropsychological Functioning
1. CHR vs. Controls
Multivariate: Raw data are presented in Table 2 and statistical results in Table 3. The
MANOVA and MANCOVA for the 8 tests were statistically significant. The MANCOVA,
controlling for FSIQ (covariate F = 0.26, p = .619, d = .16), was significant and Coding (d =.
56), COWA (d =.48), Verbal Memory (d = .45), CPT-IP (d = .39) and the composite score
(d = .45) were significant. See Figure 1 for profile.
*Results available on request from the first author.
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Univariate: Raw data are presented in Table S2 and results in Table S3. Significant tests are
Coding (d = .58), Verbal Memory (d = .54), COWA (d = .47) and CPT-IP digits (d = .43).
2. FHR vs. Controls
Multivariate: The MANOVA and MANCOVA were statistically significant. The
MANCOVA controlling for FSIQ (covariate F = 8.76, p = .004; d =.70) was not significant.
Vocabulary (d =.70), Coding (d =.66) and the composite score (d = .75) were significant.
See Figure 1 for profile.
Univariate: Significant tests were Vocabulary (d = .89), Coding (d = .66) and COWA (d = .
59).
3. CHR vs. FHR
Multivariate: The MANOVA and MANCOVA were statistically significant. The
MANCOVA controlling for FSIQ (covariate F = 4.07, p = .045; d =.44) was significant.
Verbal Memory (d =.40) was significant. The composite score was not significant (d = .16).
Comparing CHR vs. FHR, a test by group interaction was observed (F = 4.99, p < .001),
indicating a differential (i.e., non-parallel) pattern of scores (Figure 1). There was no main
effect for group, indicating comparable overall performance (F = 0.06, p = .819). Table 3
shows that the differential pattern of performance is accounted for by FHR exhibiting
somewhat greater impairment on Vocabulary, while CHR exhibited significantly greater
impairment in Verbal Memory.
Univariate: No tests were significantly different.
4. CHR+ vs. Controls
Multivariate: The MANOVA and MANCOVA were statistically significant. The
MANCOVA controlling for FSIQ (covariate F = 2.34, p = .128; d =.34) was significant.
Coding (d =.69), Verbal Memory (d = .65), Vocabulary (d =.50) and the composite score
were significant (d = .72). See Figure 1 for profile.
Univariate: Verbal Memory (d = .79), Coding (d = .68), COWA (d = .68), Vocabulary (d =
65) and CPT-IP digits (d = .62) were significant.
5. CHR− vs. Controls
Multivariate: The MANOVA and MANCOVA were statistically significant. The
MANCOVA controlling for FSIQ (covariate F = 0.05, p = .838; d =.07) was significant.
Coding (d =.50) was significant. The composite score was not significant (d = .36). See
Figure 1 for profile.
Univariate: Significant tests were Coding (d = .57), Verbal Memory (d = .46) and CPT-IP
digits (d = .39).
6. CHR+ vs. CHR−
Multivariate: The MANOVA was significant and the MANCOVA showed a marginal
trend (p = .08). The MANCOVA controlling for FSIQ (covariate F = 1.90, p = .170; d =.26)
was not significant. The composite score (d = .40) and Vocabulary (d =.46) were significant.
A test of profile shape showed no significant test-by-group interaction (F = 1.65, p = .136).
A main effect of test was observed (F = 8.56, p < .001), indicating that differential
performance was observed across tests, independent of the groups. In addition, there was a
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main effect of group, indicating that the profiles differed in overall neuropsychological
performance (F = 6.47, p = .012). See Figure 1.
Univariate: Vocabulary was significant (d = .43).
7. CHR+FH+ vs. Controls
Univariate: Because the sample was small (CHR+FH+ maximum n = 13), only the
univariate sample data was analyzed. Statistically significant, large effects were obtained on
Verbal Memory (d = .99), CPT-IP digits (d = .98), and Coding (d = .87). The overall mean
ES, weighted for the sample size for each test, suggests a dose response and is largest in
CHR+FH+ (Figure 2).
Site: Although group ascertainment differed significantly by site (see online supplement),
MANCOVAs using site showed minimal impact, affecting only one of six contrasts (CHR+
vs. CHR−; Table 3).
Sensitivity of Individual Tests: 12/48 tests (25%) in the multivariate sample and 16/48
tests (33%) in the univariate sample (which included 45% more subjects) were statistically
significant at the Bonferroni level. Coding was significant 4/6 times and Verbal Memory
was significant 3/6 times in each sample, indicating that they were most likely to show
impairment. Block Design, Trail Making B, and WCST perseverations were not significant
at the Bonferroni level in any comparisons, suggesting they are less affected in HR samples.
Prediction of Progression to Psychosis with Neuropsychological Tests: Cox regression
models were estimated to identify baseline cognitive variables that were most predictive of
time to conversion to psychosis. In the first set of analyses, only four selected variables were
examined. The composite score (χ2 (1) = 3.05, p = 0.08), FSIQ (χ2 (1) = 2.63, p = 0.11), and
Coding (χ2 = 0.14, p = 0.71) were not significant. In contrast, Verbal Memory was a
significant predictor of time to conversion (χ2 = 6.1, p = 0.01), and demonstrated a hazard
ratio of 0.79 suggesting that CHR subjects with impaired verbal memory were likely to
progress more rapidly to psychosis. A second analysis used backward selection to identify
which among the eight cognitive variables were the best predictors of rate of progression to
psychosis. The log rank test was not significant (χ2 (1) = 13.18, p = 0.11). A third Cox
regression examined whether the cognitive variables (composite, FSIQ, Coding, and Verbal
Memory) added to the multivariate NAPLS prediction model30. None contributed uniquely
to the prediction of psychosis beyond clinical variables.
Discussion
As predicted, CHR subjects were significantly impaired in neuropsychological functioning
compared to controls after statistically adjusting for age, gender and parental education, and
site, as well as for IQ, indicating that impairments were not simply a general intellectual
deficit. Impairments were significantly more severe in CHR+ than CHR− but modestly so
(composite score d = .40), suggesting that neuropsychological deficits are associated
strongly with risk states for psychosis and additionally with conversion. CHR and FHR
groups were similarly impaired in composite neuropsychological functioning relative to
controls, but their profiles differed distinctly. Thus, risk status based on clinical symptoms
and FH both index neuropsychological vulnerability to psychosis, but they appear to be
characterized by different impairments. Impairments were most severe in the converters who
also had a FH of psychosis, suggesting a synergistic, dose-response effect (Figure 2),
although this group was quite small and this result requires replication. Tests of verbal
learning and memory and processing speed were most sensitive in discriminating CHR and
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control groups, and verbal memory predicted more rapid conversion. However,
neuropsychological measures did not significantly enhance the NAPLS clinical prediction
algorithm reported previously30.
The severity and pattern of impairment in CHR compared to results from first episode
psychosis (FE) studies is informative (see Table 4). First, it is of interest that the two most
impaired tests found in FE samples, Coding and Verbal Memory, were the two most
impaired tests in our CHR+ sample. These tasks rely heavily on verbal skills, processing
speed and new learning, functions that are reliably impaired in schizophrenia, and clearly
presage the disorder. Second, tasks such as Block Design, Trail Making B, and WCST,
though impaired in FE samples, were less sensitive measures in CHR+ subjects. Tasks that
are more visual and less verbal in nature, and explicitly require executive functions, were
affected somewhat less than verbal tasks. Alternatively, the psychometric characteristics of
Verbal Memory and Coding tests may be superior to other measures, making them more
sensitive to the presence of deficits of any severity. However, because most clinical
neuropsychological tests are multifactorial, more refined cognitive neuroscience measures
are needed to determine which cognitive mechanisms are impaired.
From a staging perspective, as further explicated in Table 4, neurocognitive deficit
apparently increases in severity from prodrome to FE, and this growing impairment is
accompanied by increasing executive dysfunction4. This suggests that additional
neuropsychological deterioration in those developing psychosis may continue to occur
during the late prodromal phase, and possibly during and subsequent to the first episode of
psychosis. However, this proposition can only be addressed definitively in longitudinal
studies that monitor cognitive function in the same subjects. The literature on this issue is
quite sparse, with only one published study having similar neuropsychological data collected
relatively close to and after the first episode; significant decline was reported on two of the
four tests85.
A major strength of this study is its large sample size, larger at baseline and follow-up than
any previously published study of neurocognition in CHR individuals. Very few published
reports on CHR have included neuropsychological functioning in persons who convert to
psychosis32, 33, 39, 40, 48,49,53. With the exception of the Melbourne (n=34) 39 and German
(n=44) 52 projects, sample sizes are small (< 21 converters). Thus, this study, which
compared neuropsychological functioning on as many as 71 converters, provides the most
robust data indicating that persons who later convert to psychosis are especially impaired at
baseline (composite d = .72). While the overall (composite) ES difference between CHR+
and CHR− was modest (d =.40), the effect was consistent in that CHR+ performed worse
than CHR− on all 8 neuropsychological measures. Based on the Cox regression analyses,
only verbal memory was associated with a significant increase in time to conversion. When
the 8 neurocognitive variables, FSIQ, or the composite score were added separately to the
multivariate NAPLS prediction algorithms30, none of the prediction statistics for the
neurocognitive variables were significant, indicating that none added unique variance to
prediction beyond clinical variables. It remains possible that future large-scale studies that
include a uniformly broader range of neuropsychological tests, particularly measures of
olfaction and working memory (shown in prior studies to be associated with conversion but
unavailable in this data set), may add unique predictive power to risk algorithms.
The neuropsychological functioning of the FHR sample was consistent with the extant
literature, yielding ES differences of .20 to.70 for many functions. This suggests that a
modest proportion of the variance in neuropsychological function is putatively associated
with genetic factors, presumably expressing themselves through brain dysfunction16,17,21,28,
86–87. What is striking about our findings is that CHR and FHR had different patterns of
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impairment, and thus FHR may contribute additional cognitive impairments to CHR status.
This was observed in the larger ESs in the CHR+FH+ subgroup, although small sample size
precludes firm conclusions. Only two studies have linked FH and conversion to psychosis,
the Edinburgh50 and Palau36 HR studies. These studies used very different designs and
ascertainment criteria, making findings difficult to integrate. Nonetheless, both studies show
a trend for persons with FHR plus prodromal symptoms to be particularly
neuropsychologically impaired.
This study has a number of limitations, the most important being variability in the specific
tests administered across NAPLS sites resulting in relatively high rates of missing data for
some measures and inconsistent sample sizes across tests. We addressed this problem by
creating a multivariate sample in which we reduced the number of tests and subjects, and
imputed data. Although this resulted in substantial subject loss, we were able to demonstrate
that the results were quite consistent across the smaller multivariate subsample and the full
univariate sample as observed by comparable ESs (see Table 4). We also constrained our
conclusions about individual tests with Bonferroni corrections. Another limitation was the
domains assessed (e.g., social cognition, olfaction, and other measures of executive function
were not assessed). Future work should combine large samples with a common
neuropsychological battery, selected to maximize predictive value. In addition, because it is
quite likely that some CHR will convert to psychosis later88, “misclassifying” some subjects
as “non-converters” may have reduced the differences observed in CHR+ and CHR−
contrasts. Subjects were followed up for variable periods, but even a 2.5 year follow-up
duration is unlikely to identify all persons who convert. We also had limited data on
medication status and other treatment exposures. It will be important in future CHR studies
to account for the effects of psychopharmacological and other treatments.
Despite these limitations, our study is largely consistent with the results of other research
groups, including those comparing converters vs. non-converters53. These findings
demonstrate that prospective ascertainment of individuals at CHR for psychosis reveals
significant neuropsychological impairment, especially among those who later convert to
psychosis, and these effects are amplified among those with a FH of psychosis. Because
neuropsychological tests are relatively inexpensive, have extensive normative data, and are
heavily used by school personnel, in conjunction with FH and attenuated clinical symptoms,
they may have potential as early indicators of risk for psychosis as well as other important
outcomes such as functional disability.
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Neuropsychological Profiles of CHR (Total Sample), CHR Converters, CHR Non-
Converters, and FHR Groups Standardized Against the Normal Control Group from the
“Multivariate” Sample
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Effect Sizes (ES) reflecting comparisons of different High Risk groups with normal controls.
ESs (Cohen’s d) are averaged within group in the “Univariate” sample after weighting for
sample size across the 8 neuropsychological test variables. Data suggests a dose response
impact of both conversion and family history of psychosis. Comparisons are as follows
(average number of subjects per test per group in parenthesis: NC (n= 144): 1) CHR Non-
Converters (n=155); 2) CHR (total sample [n=242]); 3) FHR (n=45); 4) CHR Converters
(n=62); 5) CHR Converters/FH+ (n=13).
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